Our study is the first report that SMYD3 is essential for ovarian cancer proliferation and tumorigenesis, indicating the potential of SMYD3 as a new epigenetic therapeutic target for ovarian cancer. The gene discussed is SMYD3; the disease is ovarian cancer.